{"nctId":"NCT01134705","briefTitle":"Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)","startDateStruct":{"date":"2010-05"},"conditions":["Rhinitis, Allergic, Perennial"],"count":474,"armGroups":[{"label":"BDP HFA 320 Âµg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Nasal Aerosol"]}],"interventions":[{"name":"Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol","otherNames":["QNASL(TM)"]},{"name":"Placebo Nasal Aerosol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed Consent\n* Documented history of perennial allergic rhinitis\n* A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test.\n* Minimum subject-reported reflective total nasal symptom score (rTNSS) of at least 6 (out of a possible 12)\n* Other criteria apply\n\nExclusion Criteria:\n\n* History of physical findings of nasal pathology (within 60 days prior to screening visit)\n* Participation in any investigational drug study 30 days preceding screening visit\n* History of respiratory infection/disorder with 14 days preceding screening visit or during the run-in period\n* Use of any prohibited concomitant medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period","description":"Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \\& PM) using the following scale:\n\n0=absent (no sign/symptom); 1=mild (sign/symptom present, awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping).\n\nThe total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"0.14"},{"groupId":"OG001","value":"-1.6","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Six-week Treatment Period","description":"Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to assessment twice daily (AM \\& PM) using the following scale:\n\n0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptoms, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping).\n\nThe total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"0.13"},{"groupId":"OG001","value":"-1.4","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)","description":"The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.14"},{"groupId":"OG001","value":"-0.9","spread":"0.14"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":236},"commonTop":["Nasal discomfort"]}}}